oleanolic acid has been researched along with Diabetic Nephropathies in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.63) | 29.6817 |
| 2010's | 31 (81.58) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J; Xu, W; Zhang, H; Zhang, Q | 1 |
| Leehey, DJ | 1 |
| Anton, MI; Ciocoiu, M; Costea, CF; Floria, M; Gosav, EM; Hurjui, LL; Rezus, C; Seritean Isac, PN; Tanase, DM; Tarniceriu, CC | 1 |
| Chen, X; Hu, Z; Kang, L; Liu, B; Liu, Y; Niu, K; Xing, H | 1 |
| Ito, M; Nangaku, M | 1 |
| Kanda, H; Yamawaki, K | 1 |
| Gamede, M; Khathi, A; Mabuza, L; Ngubane, P | 1 |
| Bhattacharjee, N; Dewanjee, S; Dua, TK; Kalita, J; Khanra, R; Manna, P; Nandy, A; Saha, A | 1 |
| Chen, C; Huang, Z; Lai, Y; Li, P; Mou, Y; Peng, S; Tian, J; Xu, X; Xu, Y; Zhang, Y; Zhao, D | 1 |
| Toto, RD | 1 |
| Baigent, C; Lennon, R | 1 |
| Appel, GB; Block, GA; Chertow, GM; Chin, MP; Coyne, DW; Goldsberry, A; Kalantar-Zadeh, K; Meyer, CJ; Molitch, ME; Pergola, PE; Raskin, P; Rossing, P; Silva, AL; Spinowitz, B; Sprague, SM | 1 |
| Chin, MP; Goldsberry, A; McCullough, PA; Meyer, CJ; O'Grady, M; Pergola, PE; Rizk, DV; Silva, AL; Toto, R; Warnock, DG | 1 |
| Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; McCullough, PA; Meyer, CJ; Packham, D; Pergola, PE; Rossing, P; Spinowitz, B; Sprague, SM; Warnock, DG | 1 |
| Kalantar-Zadeh, K; Tayek, JA | 1 |
| Agarwal, R; Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; de Zeeuw, D; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Pergola, PE; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Warnock, DG; Wittes, J | 1 |
| Appel, G | 1 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Krauth, M; Lambers Heerspink, HJ; Linde, P; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Himmelfarb, J; Tuttle, KR | 2 |
| Akizawa, T; Audhya, P; Bakris, GL; Chertow, GM; Chin, M; Christ-Schmidt, H; de Zeeuw, D; Goldsberry, A; Houser, M; Krauth, M; Lambers Heerspink, HJ; McMurray, JJ; Meyer, CJ; Parving, HH; Remuzzi, G; Toto, RD; Vaziri, ND; Wanner, C; Wittes, J; Wrolstad, D | 1 |
| Goldsmith, DJ; Hajhosseiny, R; Jivraj, N; Khavandi, K; Malik, RA; Mashayekhi, S | 1 |
| Cooper, ME; de Haan, JB; Karagiannis, TC; Meyer, C; Sharma, A; Stefanovic, N; Tan, SM; Ward, KW; Yuen, DY | 1 |
| Chertow, GM; de Zeeuw, D | 1 |
| Chartoumpekis, DV; Sykiotis, GP | 1 |
| Kovács, T; Molnár, GA; Wittmann, I | 1 |
| Ellison, DH | 1 |
| Van Biesen, W; Van Laecke, S; Vanholder, R | 1 |
| Bhalla, V; Hall, ET | 1 |
| de Zeeuw, D; Meyer, C | 1 |
| Breyer, MD; Susztak, K | 1 |
| Mapanga, RF; Musabayane, CT; Shode, FO; Tufts, MA | 1 |
| Cooper, ME; Thomas, MC | 1 |
| Thomas, M | 1 |
| Hohenstein, B; Hugo, C | 1 |
| Abbate, M; Benigni, A; Carrara, F; Corna, D; Gaspari, F; Locatelli, M; Nava, V; Remuzzi, G; Sangalli, F; Zoja, C | 1 |
| Harris, RC | 1 |
| Rossing, P | 1 |
6 review(s) available for oleanolic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Humans; Inflammation; Multicenter Studies as Topic; Oleanolic Acid; Pentoxifylline; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.
Topics: Antioxidants; Curcumin; Diabetic Nephropathies; Humans; Intercellular Adhesion Molecule-1; Interleukin-1; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; NF-kappa B; Oleanolic Acid; Oxidative Stress; Quality of Life; Reactive Oxygen Species; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2022 |
Bardoxolone methyl: drug development for diabetic kidney disease.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Japan; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Oleanolic Acid | 2020 |
Have we reached the limits for the treatment of diabetic nephropathy?
Topics: Animals; Diabetic Nephropathies; Humans; Oleanolic Acid; Pyridoxamine; Renin-Angiotensin System; Vitamin D | 2014 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Chronic Disease; Diabetic Nephropathies; Drug Evaluation; Humans; NF-E2-Related Factor 2; Oleanolic Acid; Signal Transduction | 2012 |
6 trial(s) available for oleanolic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Oleanolic Acid; Renal Insufficiency, Chronic; Waist Circumference | 2018 |
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Glomerular Filtration Rate; Humans; Magnesium; Male; Middle Aged; Oleanolic Acid; Renal Insufficiency, Chronic | 2019 |
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Topics: Adult; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oleanolic Acid; Treatment Outcome | 2019 |
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
Topics: Anti-Inflammatory Agents; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oleanolic Acid; Prognosis; Renal Insufficiency, Chronic; Young Adult | 2013 |
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; NF-E2-Related Factor 2; Oleanolic Acid; Renal Insufficiency, Chronic; Treatment Failure; Weight Loss | 2013 |
26 other study(ies) available for oleanolic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
β-Amyrin ameliorates diabetic nephropathy in mice and regulates the miR-181b-5p/HMGB2 axis in high glucose-stimulated HK-2 cells.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; HMGB2 Protein; In Situ Hybridization, Fluorescence; Mice; MicroRNAs; Oleanolic Acid | 2022 |
Renoprotective effects of oleanolic acid and its possible mechanisms in rats with diabetic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammation; Kidney; Lipids; Male; NF-kappa B; Oleanolic Acid; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2022 |
Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Humans; Oleanolic Acid; Renal Insufficiency, Chronic; Retrospective Studies | 2019 |
Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model.
Topics: Animals; Biomarkers; Diabetic Nephropathies; Diet; Diet, High-Fat; Dietary Carbohydrates; Glomerular Filtration Rate; Hypoglycemic Agents; Kidney Function Tests; Male; Metformin; Oleanolic Acid; Oxidative Stress; Prediabetic State; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Syzygium | 2021 |
Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats.
Topics: Animals; Computer Simulation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Hyperglycemia; Inflammation; Malvaceae; Molecular Docking Simulation; Oleanolic Acid; Plant Leaves; Rats; Rats, Wistar; Streptozocin; Up-Regulation | 2017 |
Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy.
Topics: Animals; Diabetic Nephropathies; Drug Therapy; gamma-Glutamyltransferase; HEK293 Cells; Humans; Kidney; Mice; Oleanolic Acid; Rats | 2017 |
Bardoxolone-the Phoenix?
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Topics: Albuminuria; Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.
Topics: Anti-Inflammatory Agents; Diabetic Nephropathies; Early Termination of Clinical Trials; Humans; Oleanolic Acid; Proteinuria; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Spasm; Weight Loss | 2013 |
Detecting and controlling diabetic nephropathy: what do we know?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Oleanolic Acid; Renin-Angiotensin System | 2013 |
New therapies for diabetic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2013 |
Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Rats | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2014 |
The paradox of bardoxolone methyl: a call for every witness on the stand?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease?
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; Oleanolic Acid | 2014 |
The paradox created by commenting on large clinical trial results.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Renal effects of plant-derived oleanolic acid in streptozotocin-induced diabetic rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Kidney Function Tests; Male; Oleanolic Acid; Phytotherapy; Plant Extracts; Potassium; Probability; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sodium; Streptozocin | 2009 |
Diabetes: bardoxolone improves kidney function in type 2 diabetes.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Inactivation, Metabolic; Kidney Failure, Chronic; NF-E2-Related Factor 2; Oleanolic Acid | 2011 |
[Diabetes and the kidneys].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Islets of Langerhans Transplantation; Oleanolic Acid; Pancreas Transplantation | 2012 |
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Chromatography, Liquid; Diabetic Nephropathies; Disease Models, Animal; Diuresis; Drinking; Hemodynamics; Kidney; Liver; Male; Mass Spectrometry; Oleanolic Acid; Ramipril; Rats; Rats, Zucker; Renal Circulation; Triterpenes | 2013 |
The best-laid plans.
Topics: Animals; Diabetic Nephropathies; Kidney; Male; Oleanolic Acid; Triterpenes | 2013 |
Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
Topics: Animals; Clinical Trials, Phase III as Topic; Diabetic Nephropathies; Disease Models, Animal; Early Termination of Clinical Trials; Glomerular Filtration Rate; Humans; Oleanolic Acid | 2013 |